Rhythm Pharmaceuticals director Christophe Jean filed a Form 144 notice on November 17, 2026, indicating a proposed sale of 10,000 shares of common stock acquired through the exercise of stock options on the same date.

Key Highlights

  • Proposed seller: Christophe Jean, a director of Rhythm Pharmaceuticals Inc.
  • Shares proposed for sale: 10,000 shares of common stock, with an aggregate market value of $1,074,800.00 as stated in the filing.
  • Source of shares: Exercise of stock options acquired from the issuer on November 17, 2026, paid in cash.
  • Approximate date of sale: November 17, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.
  • 10b5-1 plan: The filing indicates a plan adoption date of August 18, 2026, under Rule 10b5-1.
  • Shares outstanding: 69,330,906 shares of common stock outstanding, according to the filing.
  • Prior sales: The filing reports nothing to report for securities sold during the past three months.

Director Jean's Proposed Sale Under a Pre-Established 10b5-1 Plan

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Christophe Jean, identified as a director of Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM), proposed to sell 10,000 shares of the company's common stock. The filing lists the aggregate market value of those shares at $1,074,800.00 and identifies the approximate sale date as November 17, 2026.

The filing discloses that the 10,000 shares were acquired on November 17, 2026, through the exercise of stock options granted by the issuer, with payment made in cash on the same date. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, on the NASDAQ exchange.

The notice indicates that Jean is relying on a Rule 10b5-1 trading plan adopted on August 18, 2026. By signing the filing, Jean represented that, as of the plan adoption date, he did not know of any material adverse information regarding the current and prospective operations of Rhythm Pharmaceuticals that had not been publicly disclosed. The filing reports no securities of the issuer sold by Jean during the past three months.

What Was Disclosed

Rhythm Pharmaceuticals director Christophe Jean filed a Form 144 on November 17, 2026, disclosing a proposed sale of 10,000 common shares acquired via stock option exercise, valued at $1,074,800.00 in aggregate, under a 10b5-1 plan adopted August 18, 2026.